Nabriva Therapeutics PLC represents a strong commitment to advancing the field of anti-infectives and improving patient outcomes. Their corporate philosophy revolves around innovation, scientific excellence, and dedication to bringing novel treatments to market. The company is focused on addressing the global challenge of antibiotic resistance by developing and commercializing innovative antibiotics. With a patient-centric approach, Nabriva Therapeutics PLC strives to meet unmet medical needs and provide effective solutions for serious infections. Through continuous research and development efforts, they aim to contribute to the fight against infectious diseases and improve the quality of life for patients worldwide.

Nabriva Therapeutics PLC is primarily present in the United States and Europe. The company focuses on developing innovative medications to treat serious infections. With its headquarters in Dublin, Ireland, Nabriva Therapeutics PLC has a strong presence in the European pharmaceutical market. In the United States, the company's operations center around promoting and commercializing their products to healthcare professionals and patients. Nabriva Therapeutics PLC aims to address the global need for effective antibiotics by expanding its reach and market presence.

Nabriva Therapeutics PLC has achieved several significant milestones. Firstly, the company successfully received approval from the U.S. Food and Drug Administration (FDA) for their novel antibiotic, lefamulin, designed to treat community-acquired bacterial pneumonia (CABP). This approval marked a major milestone for Nabriva Therapeutics PLC as lefamulin became the first and only systemic oral and IV treatment approved in nearly two decades for CABP patients. Additionally, the company has made progress in expanding lefamulin's availability in Europe, receiving marketing authorization in several countries. Nabriva Therapeutics PLC's achievements demonstrate their commitment to advancing innovative solutions for infectious diseases treatment.

Nabriva Therapeutics PLC is a pharmaceutical company headquartered in Dublin, Ireland. Established in 2005, Nabriva focuses on developing innovative treatments to combat serious infections. The company has a strong emphasis on research and has built a robust pipeline of potential antibiotics. Nabriva Therapeutics PLC aims to address the growing global issue of antibiotic resistance through its novel approaches. With a dedicated team of experts and strategic partnerships, Nabriva Therapeutics PLC strives to improve patient outcomes and contribute to the fight against infectious diseases.

The main competitors of Nabriva Therapeutics PLC in the market include biopharmaceutical companies such as Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc, and AstraZeneca plc. These companies are also actively involved in the development and commercialization of innovative therapeutics and solutions for various medical conditions. Nabriva Therapeutics PLC competes with these industry leaders by leveraging its unique approach, research and development pipeline, and commercialization strategies.

Nabriva Therapeutics PLC is primarily active in the pharmaceutical industry.

The business model of Nabriva Therapeutics PLC focuses on developing and commercializing innovative antibiotic treatments to address significant unmet medical needs. As a pharmaceutical company, Nabriva Therapeutics is dedicated to discovering, developing, and bringing to market novel antibiotics to combat serious infections caused by multi-drug resistant bacteria. By leveraging its expertise in antibiotics research and development, Nabriva Therapeutics aims to provide healthcare professionals with effective and safe treatment options for patients suffering from various bacterial infections. Through its continuous commitment to enhancing patient care, Nabriva Therapeutics strives to make a positive impact on global public health.

Raportul Nabriva Therapeutics preț/beneficiu este -0,02.

Raportul Nabriva Therapeutics preț/vânzări este 0,01.

Scorul de calitate AlleAktien pentru Nabriva Therapeutics este 3/10.

Cifra de afaceri a așteptată Nabriva Therapeutics este de 105,91 milioane USD.

Profitul așteptată Nabriva Therapeutics este -63,80 milioane USD.

Nabriva Therapeutics PLC is a biopharmaceutical company specializing in the research, development, and commercialization of anti-infectives. The company's business model is based on providing innovative antibiotic products for the treatment of bacterial infections. They focus on developing and approving products specifically targeted against bacterial infectious diseases, including skin and soft tissue infections, outpatient respiratory tract infections, and nosocomial infections. Nabriva Therapeutics is committed to discovering and developing new and innovative therapies to meet the global demand for more effective antibiotics. The company has become a leading player in antibiotic development by conducting comprehensive drug research and development to address treatment gaps. Their three main products are Mavenclad, CONTEPO, and Lefamulin. Mavenclad is an oral Cladribine preparation for the treatment of relapsing multiple sclerosis (MS), representing a significant milestone in MS patient treatment. CONTEPO is an intravenous antibiotic for the treatment of complicated urinary tract infections, including pyelonephritis. It is the first antibiotic approved for treating infections caused by ESBL-producing Enterobacteriaceae, a growing global problem of antibiotic resistance. Lefamulin is an oral and intravenous antibiotic for the treatment of community-acquired bacterial pneumonia (CABP). It is the first antibiotic approved for CABP in the last 20 years. Nabriva Therapeutics operates a strong and extensive research and development program based on clinical studies to demonstrate the effectiveness and safety of their products. Additionally, they have a dynamic marketing program that collaborates closely with healthcare providers, clinicians, and patients to increase the availability and access to their products. The company distributes and markets its products in collaboration with a global list of partners, including a strategic partnership with Merck Sharp & Dohme Corp. (MSD) to drive the global introduction of Lefamulin. Overall, Nabriva Therapeutics has built a strong market position in the global anti-infective industry and has an excellent reputation in the field. They are positioned as a leader in the development and commercialization of antibacterial therapeutics, and with their strong research and development department and innovative products, they are on track to continue delivering successful antibiotic products to meet global demand.

Nabriva Therapeutics distribuie un dividend de 0 USD în plăți anuale.

Dividenda nu poate fi calculată în prezent pentru Nabriva Therapeutics sau compania nu distribuie dividende.

Codul ISIN pentru Nabriva Therapeutics este IE00BL53QQ85.

Codul WKN al Nabriva Therapeutics este A2QKWR.

Ticker-ul pentru Nabriva Therapeutics este NBRV.

În ultimele 12 luni, Nabriva Therapeutics a plătit un dividend în valoare de . Aceasta corespunde unei randamente a dividendului de aproximativ . Pentru următoarele 12 luni, Nabriva Therapeutics va plăti probabil un dividend de 0 USD.

Randamentul dividendelor pentru Nabriva Therapeutics este în prezent de .

Nabriva Therapeutics plătește un dividend trimestrial. Acesta este distribuit în lunile .

Nabriva Therapeutics a plătit dividende în fiecare an, în ultimii 0 ani.

Pentru următoarele 12 luni se așteaptă dividende în valoare de 0 USD. Acest lucru corespunde unei randamente a dividendelor de 0 %.

Nabriva Therapeutics este atribuit sectorului 'Sănătate'.

Pentru a primi ultimul dividend de Nabriva Therapeutics de la 11.07.2024 în valoare de 0 USD, trebuia să deții acțiunea în portofoliu înainte de ziua Ex-Tag de pe 11.07.2024.

Ultima plată a dividendului a fost efectuată la 11.07.2024.

În anul 2023, Nabriva Therapeutics a distribuit 0 USD sub formă de dividende.

Dividendele de la Nabriva Therapeutics sunt distribuite în USD.